Skip to content

Effect of Perioperative Morphine Analgesia Strategy on Reintubation Rate in Patients After Cardiac Surgery: A Single-Center Prospective Randomized Controlled Trial

Effect of Perioperative Morphine Analgesia Strategy on Reintubation Rate in Patients After Cardiac Surgery: A Single-Center Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111495
Enrollment
Unknown
Registered
2025-10-31
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative complications of cardiac surgery

Interventions

Trial Group/ Morphine Group:Perioperative morphine analgesia strategy: Morphine hydrochloride injection is used for analgesia. Administration via continuous intravenous infusion combined with PRN dosi
Control Group/ Fentanyl Group:Perioperative fentanyl-based analgesia strategy: The attending physician selects from the following fentanyl analogs based on patient condition, drug availability, and cl

Sponsors

Mianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for this study included age ranging from 18 to 80 years old, undergoing elective cardiac surgery (valve surgery, coronary artery bypass grafting or combined surgery), with an expected postoperative mechanical ventilation time of = 6 hours, and the patient or their legal representative signing the informed consent form.

Exclusion criteria

Exclusion criteria: Patients who have been using opioids for more than three months before surgery, are allergic to morphine or fentanyl, have severe liver and kidney dysfunction (Child-Pugh C grade for liver function, eGFR < 30 ml/min/1.73 m^2 for kidney function), have severe respiratory system diseases (COPD GOLD 4 grade), need ECMO support due to severe intraoperative complications, and have an expected survival period of less than 28 days.

Design outcomes

Primary

MeasureTime frame
Re-intubation rate within 48 hours;

Secondary

MeasureTime frame
Improvement degree of dyspnea;Mechanical ventilation time;Comprehensive efficacy evaluation (including satisfaction with analgesic effect, patient comfort score, and healthcare provider assessment);

Countries

China

Contacts

Public ContactXu Jinlong

Mianyang Central Hospital

871922384@qq.com+86 182 2759 6474

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026